Q&A with Dr. Salla Keskitalo: Challenges and Opportunities in Studying Rare and Ultra-rare Autoimmune Diseases

Dr. Salla Keskitalo is a Senior Research Scientist at the University of Helsinki and a recent winner of NanoString’s Autoimmunity Grant Program. She made time to speak with us about her work studying rare and ultra-rare autoimmune diseases. NS: Tell...

Q&A with Drs. Torsten Nielsen and Tony Ng and Angela Goytain: Development of a Sarcoma Gene Fusion Assay Faster Than FISH and Simpler than NGS

The NanoString nCounter is Research Use Only and not for diagnostic use. The views expressed herein are solely those of the interviewed researchers. Torsten Nielsen, MD, PhD is a pathologist and clinical scientist at the University of British Columbia (BC)...

Q&A with Dr. Gregory Carter: Developing Computational Strategies and the MODEL-AD Consortium

Gregory Carter, Ph.D., is an Associate Professor at The Jackson Laboratory. His work is focused on developing computational strategies using genetic data to understand complex genetic systems. We recently spoke with Dr. Carter about his research and the MODEL-AD consortium....

Meta-analysis of AMP-AD Datasets Defines the Transcriptional Landscape of Alzheimer’s Disease

The Accelerating Medicines Partnership - Alzheimer’s Disease (AMP-AD) Consortium was formed to accelerate the development of diagnostics and therapeutics for this devastating and complex disease. One roadblock to development is the lack of good pre-clinical models, as efficacy in clinical...

/ January 31, 2019

NanoString-based publications 2018: A year in review

2018 was an incredibly productive year for scientific publications showcasing the NanoString platform and assays. We added nearly 500 publications of various scientific disciplines which are available on our website here. Below are some of the highlights of the year. It’s...

/ January 21, 2019